A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 5
- 主要终点
- Dose Escalation - Determine Maximum Tolerated Dose (MTD)
研究概览
简要总结
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
详细描述
CDX-014 is an antibody-drug conjugate that binds to a protein called TIM-1, which is found on a high percentage of kidney cells that are clear or papillary and ovarian cancer cells that are clear cell.
The study will enroll patients with advanced or metastatic renal cell carcinoma and ovarian clear cell carcinoma to determine the safety and efficacy of CDX-014.
This study will include a Dose-Escalation Phase followed by a Cohort Expansion Phase
All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of advanced or metastatic clear cell or papillary renal cell carcinoma or histologically confirmed clear cell ovarian carcinoma.
- •For RCC, at least two prior anticancer regimens (one must be a VEGF-targeted TKI), or are otherwise inappropriate candidates for all approved therapies. For OCCC, at least one line of prior therapy with a platinum and taxane regimen.
- •Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
- •Measureable (target) disease.
- •Must have available tumor tissue for TIM-1 expression testing
- •Life expectancy ≥ 3 months
- •If of childbearing potential (male or female), agrees to use effective contraception during study treatment and for at least 6 months following last treatment dose.
排除标准
- •Prior therapy containing MMAE
- •Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within 3 weeks of study treatment for OCCC
- •Tyrosine kinase inhibitor (TKI) therapy within 2 weeks or at least 5 half-lives (whichever is longer) prior to planned start of study treatment.
- •Monoclonal antibody therapy within 4 weeks prior to the planned start of study treatment.
- •Radiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).
- •Major surgery or significant traumatic injury within 4 weeks prior to study entry.
- •Use of other investigational drugs within 2 weeks or 5 half-lives (whichever is longer) prior to study treatment.
- •Concurrent severe and/or uncontrolled medical conditions (uncontrolled diabetes or infection), known infection with HIV, Hepatitis B or Hepatitis C.
- •Brain metastases, unless previously treated and asymptomatic and not progressive for 2 months.
- •Significant cardiovascular disease (including congestive heart failure).
- •Other malignancy except for treated and cured basal or squamous cell skin cancer, cured in situ cancers, or other cancer from which the patient has been disease-free for ≥ 3 years.
- •Active systemic infection requiring treatment. Infection controlled by oral therapy will not be exclusionary.
- •Chronic use of systemic corticosteroid above an accepted physiologic dose (5mg per day of prednisone or equivalent) within 7 days of enrollment except when used as premedication
研究组 & 干预措施
CDX-014
During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
The planned dose of CDX-014 depends on the cohort assigned at enrollment.
干预措施: CDX-014 (Drug)
结局指标
主要结局
Dose Escalation - Determine Maximum Tolerated Dose (MTD)
时间窗: Within 21 days after first dose.
Determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of CDX-014 (in mg/kg). MTD will be defined as the highest dose-level where DLT (dose-limiting toxicity) occurs in less than 33% of treated patients.
Cohort Expansion - Assess Objective Response Rate (ORR)
时间窗: Evaluated every 6-9 weeks following treatment initiation until treatment is discontinued or disease progression, up to 5 years.
Objective Response Rate (ORR) defined as the proportion of patients who achieve radiographic partial or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline.
次要结局
未报告次要终点